In this volume, Liu et al. perform a rigorous meta-analysis aimed to cover three clinically relevant questions regarding the use of rituximab in patients with IgG4-related disease (IgG4-RD) [1]. Is rituximab effective in inducing disease remission? Is rituximab effective in preventing disease flares? Is rituximab safe in patients with IgG4-RD?
